Pembelian
Breaking out of the flag
3 month flag setup and it's finally stepping out of that trend today. We should see it head to around $40, pullback a little bit, and then breakout for new all time highs. Alternatively, a more optimistic look would be "W" pattern and it breaks out when it hits $40 without the pullback.
Approval for Solithromycin is expected in mid-2016. At $1.6B market cap, it is still very undervalued for what is one of the most important antibiotics that will be approved this decade. Peak sales estimates have been up to $2B/year worldwide, and will likely be more if other indications are added. This why I believe management will not consider a buyout until after the NDA has been submitted later this year and any offer will need to be at least $125 ($5.5B) to $200 ($8.6B) range to match the sales/pipeline potential.
Approval for Solithromycin is expected in mid-2016. At $1.6B market cap, it is still very undervalued for what is one of the most important antibiotics that will be approved this decade. Peak sales estimates have been up to $2B/year worldwide, and will likely be more if other indications are added. This why I believe management will not consider a buyout until after the NDA has been submitted later this year and any offer will need to be at least $125 ($5.5B) to $200 ($8.6B) range to match the sales/pipeline potential.
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.